Hox-Dependent Coordination of Cardiac Cell Patterning and Differentiation

2019 ◽  
Author(s):  
Sonia Stefanovic ◽  
Brigitte Laforest ◽  
Jean-Pierre Desvignes ◽  
Fabienne Lescroart ◽  
Laurent Argiro ◽  
...  
Keyword(s):  
Cell Patterning ◽  
Cardiac Cell

The impact of age on the outcome of cardiac cell therapy

2010 ◽  
Vol 58 (S 01) ◽  
Author(s):  
B Nasseri ◽  
M Kukucka ◽  
SJ Kim ◽  
YH Choi ◽  
KS Kang ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cardiac Cell ◽  
Cardiac Cell Therapy ◽  
The Impact

Placenta-derived mesenchymal stem cells for allogenic cardiac cell therapy

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
R Roy ◽  
M Kukucka ◽  
D Messroghli ◽  
A Brodarac ◽  
M Becher ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cell Therapy ◽  
Cardiac Cell ◽  
Cardiac Cell Therapy

Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell

2020 ◽  
Vol 20 ◽  
Author(s):  
Shahzad Khan ◽  
Syed S. Ahmad ◽  
Mohammad A. Kamal
Keyword(s):  
Diabetic Cardiomyopathy ◽  
Immune Modulation ◽  
Cell Injury ◽  
Interstitial Fibrosis ◽  
Systolic Dysfunction ◽  
Therapeutic Strategies ◽  
Cardiac Cell ◽  
Clinical Heart Failure ◽  
Artery Disease ◽  
Apoptosis And Necrosis

: Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradual failing heart with detrimental cardiac remodellings such as fibrosis and diastolic and systolic dysfunction, which is not directly attributable to coronary artery disease. Insulin resistance and resulting hyperglycemia is the main trigger involved in the initiation of diabetic cardiomyopathy. There is a constellation of many pathophysiological events such as lipotoxicity, oxidative stress, inflammation, inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis which ultimately culminates into interstitial fibrosis, cardiac stiffness, diastolic dysfunction initially and later systolic dysfunction too. These events finally lead to clinical heart failure of DCM. Herein, we have briefly discussed the pathophysiology of DCM. We have also briefly mentioned potential therapeutic strategies currently used for DCM.

scholarly journals Biofilm Lithography enables high-resolution cell patterning via optogenetic adhesin expression

2018 ◽  
Vol 115 (14) ◽  
pp. 3698-3703 ◽  
Author(s):  
Xiaofan Jin ◽  
Ingmar H. Riedel-Kruse
Keyword(s):  
Escherichia Coli ◽  
Cell Patterning ◽  
Biophysical Model ◽  
Microbial Consortia ◽  
Bacterial Biofilms ◽  
Surface Pretreatment ◽  
Resolution Cell ◽  
Stimulation Of

Bacterial biofilms represent a promising opportunity for engineering of microbial communities. However, our ability to control spatial structure in biofilms remains limited. Here we engineerEscherichia coliwith a light-activated transcriptional promoter (pDawn) to optically regulate expression of an adhesin gene (Ag43). When illuminated with patterned blue light, long-term viable biofilms with spatial resolution down to 25 μm can be formed on a variety of substrates and inside enclosed culture chambers without the need for surface pretreatment. A biophysical model suggests that the patterning mechanism involves stimulation of transiently surface-adsorbed cells, lending evidence to a previously proposed role of adhesin expression during natural biofilm maturation. Overall, this tool—termed “Biofilm Lithography”—has distinct advantages over existing cell-depositing/patterning methods and provides the ability to grow structured biofilms, with applications toward an improved understanding of natural biofilm communities, as well as the engineering of living biomaterials and bottom–up approaches to microbial consortia design.

Flexible and Bendable Acoustofluidics for Particle and Cell Patterning

2021 ◽  
pp. 106536
Author(s):  
Sadaf Maramizonouz ◽  
Xiang Tao ◽  
Mohammad Rahmati ◽  
Changfeng Jia ◽  
Ran Tao ◽  
...  
Keyword(s):  
Cell Patterning

scholarly journals The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field

2021 ◽  
Vol 22 (3) ◽  
pp. 1331
Author(s):  
Daniela Sorriento ◽  
Guido Iaccarino
Keyword(s):  
Fabry Disease ◽  
Molecular Mechanisms ◽  
Cell Damage ◽  
Research Field ◽  
Cardiac Cell ◽  
Lysosomal Storage ◽  
Clinical Level ◽  
New Findings ◽  
Alpha Gene ◽  
Alpha Galactosidase

Fabry disease (FD) is a lysosomal storage disorder, depending on defects in alpha-galactosidase A (GAL) activity. At the clinical level, FD shows a high phenotype variability. Among them, cardiovascular dysfunction is often recurrent or, in some cases, is the sole symptom (cardiac variant) representing the leading cause of death in Fabry patients. The existing therapies, besides specific symptomatic treatments, are mainly based on the restoration of GAL activity. Indeed, mutations of the galactosidase alpha gene (GLA) cause a reduction or lack of GAL activity leading to globotriaosylceramide (Gb3) accumulation in several organs. However, several other mechanisms are involved in FD’s development and progression that could become useful targets for therapeutics. This review discusses FD’s cardiovascular phenotype and the last findings on molecular mechanisms that accelerate cardiac cell damage.

Sign in / Sign up

Export Citation Format

Share Document